Patents by Inventor Chelsie Macedo

Chelsie Macedo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD123-binding polypeptides and uses thereof
    Patent number: 11919963
    Abstract: Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: March 5, 2024
    Assignee: Inhibrx, Inc.
    Inventors: Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Multivalent and Multispecific 41BB-Binding Proteins
    Publication number: 20230416387
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: December 16, 2022
    Publication date: December 28, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • CD123-Binding Polypeptides and Uses Thereof
    Publication number: 20230065306
    Abstract: Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: August 1, 2022
    Publication date: March 2, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • PDL1-binding proteins
    Patent number: 11566078
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: January 31, 2023
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • CD123 TARGETED IMMUNOTHERAPIES
    Publication number: 20220315638
    Abstract: The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
    Type: Application
    Filed: May 7, 2020
    Publication date: October 6, 2022
    Applicants: 2SEVENTY BIO, INC., INHIBRX, INC.
    Inventors: JORDAN JARJOUR, MARK POGSON, WAI-HANG LEUNG, CHELSIE MACEDO, KYLE JONES, WILLIAM CRAGO, ANDREW HOLLANDS, MILTON MA, JOHN C. TIMMER, BRENDAN P. ECKELMAN
  • CD123-binding polypeptides and uses thereof
    Patent number: 11434297
    Abstract: Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: September 6, 2022
    Assignee: Inhibrx, Inc.
    Inventors: Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Multivalent and Multispecific OX40-Binding Fusion Proteins
    Publication number: 20220106397
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Application
    Filed: August 10, 2021
    Publication date: April 7, 2022
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • CD123-Binding Polypeptides and Uses Thereof
    Publication number: 20200347142
    Abstract: Provided herein are VHH-containing polypeptides that bind CD123. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: May 1, 2020
    Publication date: November 5, 2020
    Applicant: Inhibrx, Inc.
    Inventors: Chelsie Macedo, Kyle Jones, William Crago, Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Multivalent and Multispecific 41BB-Binding Fusion Proteins
    Publication number: 20200199243
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: October 15, 2019
    Publication date: June 25, 2020
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux